Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative cell therapies for cancer and other life-threatening diseases. Founded in 2004, Bellicum has made significant strides in the field of immunotherapy, particularly with its proprietary GoCAR-T™ technology, which enhances the efficacy and safety of CAR T-cell therapies. With a strong presence in the oncology sector, Bellicum is dedicated to advancing its core products, including BPX-601 and BPX-701, which are designed to target specific cancer antigens. The company has garnered attention for its unique approach to cell therapy, positioning itself as a leader in the rapidly evolving landscape of cancer treatment. Bellicum's commitment to innovation and patient-centric solutions underscores its notable achievements in the biopharmaceutical industry.
DitchCarbon Score
How does Bellicum Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bellicum Pharmaceuticals, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bellicum Pharmaceuticals, Inc.'s reported carbon emissions
Bellicum Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. As there are no emissions data or reduction initiatives available, it is unclear how Bellicum Pharmaceuticals is addressing its carbon footprint or contributing to climate action within the pharmaceutical industry. The lack of reported emissions and commitments suggests a potential area for improvement in transparency and environmental responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bellicum Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
